Keyphrases
Chikungunya Virus (CHIKV)
100%
Phase 1 Clinical Trial
100%
Neutralizing Antibodies
100%
Virus Lineages
100%
ChAdOx1
100%
Tolerability
33%
Infected Individual
16%
T Cell Response
16%
Immunogenicity
16%
Vaccination
16%
Re-emerging
16%
Polyprotein
16%
Healthy Volunteers
16%
Adenovirus Vaccine
16%
Intramuscular Injection
16%
Mosquito-borne Viruses
16%
Self-limiting
16%
Adverse Events
16%
Seroconversion
16%
Arthralgia
16%
PRNT50
16%
Capsid
16%
Dose Escalation
16%
Serious Adverse Reaction
16%
Swift
16%
Trial Registries
16%
Broadly Neutralizing Antibodies
16%
Phase 1 Trial
16%
Simian Adenovirus
16%
First-in-human Trials
16%
Medicine and Dentistry
Clinical Trial
100%
Single Drug Dose
100%
Chikungunya Virus
100%
Neutralizing Antibody
100%
Adverse Event
40%
Virus Capsid
20%
T-Cell Response
20%
Volunteer
20%
Polyprotein
20%
Immunogenicity
20%
Arthralgia
20%
Seroconversion
20%
Intramuscular Injection
20%
Simian Virus
20%
Mosquito-Borne Virus
20%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
100%
Neutralizing Antibody
100%
Chikungunya Virus
100%
Adverse Event
40%
Tolerability
40%
Immunogenicity
20%
Normal Human
20%
Arthralgia
20%
Polyprotein
20%
Simian Virus
20%
Intramuscular Injection
20%
Immunology and Microbiology
Lineages
100%
Neutralizing Antibody
100%
Chikungunya Virus
100%
T Cell
20%
Capsid
20%
Immunogenicity
20%
Normal Human
20%
Seroconversion
20%
Simian Virus
20%
Virus
20%